Serious Adverse Events

24 weeks

48 weeks

PEGASYSÆRBV 800

PEGASYSÆRBV 1000/1200

PEGASYSÆRBV 800

PEGASYSÆRBV 1000/1200

3%

7%

9%

10%

%

3%

4%

3%

1%

Previous slide

Next slide

Back to first slide

View graphic version

Increase in SAEs seen as duration increases (also seen with increased RBV dose for 24 wk groups)

Note: these are ALL SAEs (if look just at those considered ërelatedí the numbers areÖ.1% 3% 4% 3%)

NOTE: slide will be modified to show the ërelatedí numbers also